The documentation of the impacts on the clinical symptoms and the immune response showed that the selected MSC exosome preparation helped to suppress GvHD symptoms in vivo.
Since the in vivo administration appears to be safe, MSC exosome administration of selected preparations turned out to be a promising new treatment option in the prevention and therapy of diseases associated with acute inflammatory processes, such as GvHD, stroke, heart-attack and neonatal damages of the brain and lungs.
On behalf of the University Duisburg-Essen, PROvendis offers access to rights for commercial use as well as the opportunity for further co-development.
In case of interest, we are pleased to inform you about the current status of the patent.
Kordelas, L. et al. (2014) MSC-derived exosomes: a novel tool to treat therapy-refractory graft-versus-host disease. Leukemia 28(4):970-3